Person:
ÇAKIR, FATMA BETÜL

Profile Picture
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
FATMA BETÜL
Last Name
ÇAKIR
Name
Email Address
Birth Date

Filters

20133
Reset filters

Settings

Author: Kebudi, Rejin × Author: Görgün, Ömer × Type: Article ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Pediatric diffuse intrinsic pontine glioma patients from a single center
    (2013-04-01) Kebudi, Rejin; ÇAKIR, FATMA BETÜL; Yaman-Ağaoğlu, Fulya; Görgün, Ömer; Ayan, İnci; Darendeliler, Emin; ÇAKIR, FATMA BETÜL
    The prognosis of children with diffuse intrinsic pontine gliomas (DIPG) is dismal. This study aims to evaluate the characteristics and treatment outcome of children with DIPG in a single center.
  • No Thumbnail Available
    PublicationMetadata only
    Interferon-? for unresectable progressive and symptomatic plexiform neurofibromas
    (2013-04-01) Kebudi, Rejin; ÇAKIR, FATMA BETÜL; Görgün, Ömer; ÇAKIR, FATMA BETÜL
    Neurofibromas are the most common manifestations of neurofibromatosis type-1. They occasionally cause pain or progressive loss of function due to nerve compression. Optimal treatment approach is still challenging and the current treatment results are not satisfactory. Four cases of plexiform neurofibromas with various clinical presentations and an addendum to a previously published report on a patient who had relief from pain and/or regression of tumor volume after treatment with interferon-alpha 2a are presented.
  • No Thumbnail Available
    PublicationMetadata only
    A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors
    (2013-04-01) Kebudi, Rejin; Yaman-Ağaoğlu, Fulya; ÇAKIR, FATMA BETÜL; Görgün, Ömer; Darendeliler, Emin; ÇAKIR, FATMA BETÜL
    Purpose: Topotecan has recently been used in the treatment of pediatric cancer. We evaluated our experience with the modified combination of vincristine, topotecan, and cyclophosphamide (VTC) given in 3 days, in children with recurrent Ewing sarcoma. Method: Children received vincristine (1.5 mg/m(2)/1st day), cyclophosphamide (600 mg/m(2)/day x 2 days) + mesna, and topotecan (1 mg/m(2)/day x 3 days) every 21 days. Result: A total of 118 courses of VTC were given to 13 patients. One patient received VTC both at first and at second relapse. Thus, 14 relapse episodes in 13 patients were evaluated. After three courses of VTC chemotherapy (CT), two achieved complete response (CR), five achieved partial response, thus an objective response was attained in 7/14 (50%) episodes. Two patients had stable disease and two patients progressed. In three episodes, CR was achieved by surgery before CT. One of them had a second relapse and attained CR with VTC. Median time from diagnosis to relapse was 23 months (5-45 months). Site of relapse was local in four patients, and metastatic in 10 episodes of nine patients. Seven patients are alive, three with no evidence of disease and four alive with disease; six have died of disease. Local treatment was used in 11 episodes. The toxicity of the VTC combination was limited mainly to the hematopoietic system. Conclusion: In conclusion, the modified VTC protocol in 3 days every 3 weeks seems to be effective and tolerable in children and adolescents with recurrent/progressive Ewing sarcoma.